Introduction: Adductor spasmodic dysphonia (ADSD) is one of the most disabling voice disorders with no permanent cure. Patients with ADSD suffer from poor voice quality and repeated interruption of phonation that leads to limitations in daily communication. Botox (BT) injection, considered the gold standard treatment for ADSD, reduces the amount of voice breaks and improves voice quality for a limited period. In this study, patients with ADSD were followed after a single BT injection to track the changes in QOL and perceptual voice quality over a 6-month period.
Method: This is a prospective and longitudinal study. Fifteen patients with ADSD were evaluated preinjection and 1, 3, and 6 months postinjection. They completed the Voice Activity and Participation Profile-Persian Version (VAPPP) and read a passage at each recording period. Perceptual assessment was done by three expert speech-language pathologists with knowledge of ADSD using the grade, roughness, breathiness, asthenia, strain (GRBAS) scale. The data were analyzed using Friedman, Wilcoxon, and McNemar tests. The significance level was set at P < 0.05.
Results: The VAPPP total score and each of the domain scores reached their peak scores at 3 months postinjection. At 6 months postinjection, the VAPPP scores increased significantly in comparison with the 3-month scores and but were lower than preinjection scores. GRBAS results also indicated that patients' voices at 1 and 3 months postinjection were significantly less severe in terms of strain and roughness (P = 0.01; P < 0.001, respectively).
Conclusion: BT injection resulted in improvement of subjects' QOL. The improvement was greatest at 3 months postinjection but remained above the preinjection values at 6 months after injection. The voice quality also improved but was not judged as normal.
Download full-text PDF |
Source |
|---|---|
| http://dx.doi.org/10.1016/j.jvoice.2018.04.023 | DOI Listing |
Publication Analysis
Top Keywords
Similar Publications
Diffusion Tensor Imaging Analysis Along the Perivascular Space (DTI-ALPS) Demonstrates That Sleep Disorders Exacerbate Glymphatic Circulatory Impairment and Cognitive Impairment in Patients with Alzheimer's Disease.
Nat Sci Sleep
December 2024
Department of Radiology, The First Affiliated Hospital of Soochow University, Suzhou, 215006, People's Republic of China.
Objective: Sleep disorders are common in Alzheimer's disease (AD) patients and can impair the glymphatic system, leading to cognitive decline. This study aimed to investigate whether AD patients with sleep disorders exhibit worse glymphatic function and more severe cognitive impairment compared to those without sleep disorders and to explore the underlying molecular imaging mechanisms.
Methods: This study included 40 AD patients with sleep disorders (ADSD), 39 cognitively matched AD patients without sleep disorders (ADNSD), and 25 healthy middle-aged and elderly controls (NC).
Myoneurectomy for Adductor Spasmodic Dysphonia: Long-Term Outcomes, Complications, and Recurrence.
Laryngoscope
November 2024
Department of Otorhinolaryngology, University of Sao Paulo School of Medicine, Sao Paulo, Brazil.
Article Synopsis
- The study aimed to assess the long-term effectiveness and safety of endoscopic myoneurectomy (EMN) of the thyroarytenoid muscle in treating adductor spasmodic dysphonia (AdSD), focusing on vocal outcomes and complications.
- Out of 48 patients treated, 79.2% experienced success, with significant improvements in vocal function reflected in a drop in the Voice Handicap Index score from 97 to 26 post-treatment.
- While some patients faced adverse effects like granulomas and glottic insufficiency, the procedure demonstrated high success rates and minimal complications, highlighting its benefits for vocal improvement.
Transnasal Endoscopic Injection of Botulinum Toxin in Patients with Adductor Spasmodic Dysphonia.
Iran J Otorhinolaryngol
September 2024
Department of Otorhinolaryngology - Head and Neck Surgery, American University of Beirut Medical Center, Beirut, Lebanon.
Introduction: Adductor Spasmodic Dysphonia (ADSD) is the most common form of spasmodic dysphonia. It encompasses various symptoms affecting voice and speech. The objective of this study is to report the management of patients with ADSD using the transnasal endoscopic approach for laryngeal Botulinum Toxin (Botox) injection.
View Article and Find Full Text PDFIntractable Aspiration Treated With Laryngectomy After SLAD-R Surgery: A Case Report.
Laryngoscope
November 2024
Department of Otolaryngology-Head and Neck Surgery, Center for Voice, Airway, and Swallowing, Medical College of Georgia, Augusta, Georgia, U.S.A.
A variety of surgical treatment options exist for adductor spasmodic dysphonia (ADSD) with selective adductor recurrent laryngeal nerve denervation and reinnervation (SLAD-R) being one of the more popular. We present a case of bilateral vocal fold paralysis (BVFP) for SLAD-R resulting in the need for total laryngectomy. We suggest BVFP is more common than reported and that we all must insure optimal long term follow up of our surgical patients.
View Article and Find Full Text PDFTremor Makes a Difference: A Comparative Study of the Demographics and Treatment Outcomes in Patients With Adductor Spasmodic Dysphonia With or Without Vocal Tremor.
J Voice
February 2024
Department of Otolaryngology, Head and Neck Surgery, Mayo Clinic, Phoenix, Arizona. Electronic address:
Objectives: This study aims to evaluate the demographic differences between those with adductor spasmodic dysphonia with vocal tremor (AdSD(+)VT) and those without vocal tremor (AdSD(-)VT) and to analyze their response to treatment with botulinum neurotoxin (BoNT-A).
Study Design: Retrospective cohort study.
Methods: A database review of all spasmodic dysphonia patients treated with BoNT from 1989 to 2018 at the Mayo Clinic in Arizona was performed.
Want AI Summaries of new PubMed Abstracts delivered to your In-box?
Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!